Table 1.
Subject Data
Subject | Sex | Age (years) | Treatment Group | Lesion Hemisphere | BrdU Survival Time (days) | Recovery Time (days)* | Mean Grasp Assessment* | Supplier |
---|---|---|---|---|---|---|---|---|
SM014j | M | 8.5 | Placebo | L | 110 | 54 | 7.68 | CPRC |
SM018j | M | 9.6 | Placebo | L | 92 | 96 | 6.46 | CPRC |
SM020j | M | 9.3 | Placebo | R | 106 | 96 | 6.58 | CPRC |
SM022j | M | 10.6 | Placebo | R | 138 | 96 | 6.46 | CPRC |
SM016j | M | 10.1 | hUTC Treated | L | 116 | 56 | 7.88 | CPRC |
SM017j | M | 8.6 | hUTC Treated | L | 99 | 35 | 7.72 | CPRC |
SM021j | M | 11.5 | hUTC Treated | R | 111 | 51 | 7.80 | CPRC |
SM024j | M | 12.1 | hUTC Treated | L | n/a | 48 | 7.86 | YNPRC |
Abbreviations: hUTC, human umbilical tissue derived cells (CNTO0007, Advanced Technologies and Regenerative Medicine, LLC, New Brunswick, NJ). CPRC, Caribbean Primate Research Center, University of Puerto Rico, San Juan, PR. YNPRC, Yerkes National Primate Research Center, Emory University, Atlanta, GA. BrdU, Bromodeoxyuridine.
Previously published data in Moore et al., 2013 (used in correlation studies in the current study)